INPUD showcases the power and impact of peer-led networks and argues for more significant and sustainable funding to build on their success.

Batchelder et al. draw links between internalised shame and guilt and challenges to reduce stimulant use.

Lamdin et al. provide further evidence on the health benefits associated with these harm reduction interventions.

Transform provides a summary of key available data on which to assess the effectiveness of the MDA 1971, covering impacts in terms of the criminal legal system, health and trends in drug markets.

Otiashvili et al. suggest vending machines are a valuable tool to provide harm reduction equipment to marginalised populations.

Harm Reduction International provides an update on legislative, policy and practical developments related to the use of capital punishment for drug offences.

The INCB reviews the functioning of the international drug control system and includes an analysis of the availability of controlled substances for medical and scientific purposes, particularly in humanitarian emergencies.

TNI maps out the gendered dynamics of drug policy in Myanmar, drawing from on-the-ground conversations with women involved in the drugs market.

The HIV Policy Lab provides an overview of the state of national HIV laws and policies as of the end of 2021.

Women Beyond Walls makes a compelling case for the need to resource work with and for women and girls impacted by the criminal legal system, including as a result of drug criminalisation.

IDPC presents key research on how the Committee on NGOs has effectively restricted civic space for drug NGOs wishing to engage in UN proceedings, and offers key recommendations for member states as they are preparing to elect new members of the Committee on NGOs in April 2022.

UNODC explores processes of heroin manufacture, the sourcing of morphine and opium, and the drivers of the industry in the region.

The NZ Drug Foundation's analysis zooms into key questions such as changes in the domestic legal framework, impact on social equity and harm reduction.

The Forum provided a space for UN, state and civil society representatives to consider how best to progress health, human rights and development in relation to drug policies.

The American Medical Association calls for increased access to healthcare and harm reduction efforts as part of a response to the growing overdose death rates in the United States.

EHRA describe key budget advocacy initiatives and HIV donor support for them.

The second issue of CHECK is dedicated to opioid agonist therapies, featuring experiences by service providers and clients.

Shaleen Title lays out a set of policy proposals to promote the growth of a diverse and competitive market, centring consumers and public health while building on effective equity programs already at work in state markets.

Handanagic et al. provide updated prevalence estimates of HIV infection and behaviours associated with HIV infection since the last NHBS survey among people who inject drugs in 2015, and represents a snapshot of the HIV prevention landscape for people who inject drugs before the COVID-19 pandemic.

Gabri et al. conclude that changes in cannabis legislation do not have an impact on the prevalence of recreational cannabis use among youth and young adults in Europe.